This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/drugbank/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/chemspider/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00416/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00416
rdf:type
n3:Drug
n3:description
Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market.
n3:group
withdrawn
n3:halfLife
3 to 4 hours
n3:indication
For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
n3:manufacturer
n5:271B47C8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00416 n16:DB00416
dcterms:title
Metocurine Iodide
adms:identifier
n7:PA164749507 n9:24244 n10:D00761 n11:22666 n12:DB00416 n15:46507773
n3:mechanismOfAction
Metocurine iodide antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
n3:synonym
Metokurinjodid (+)-O,O'-Dimethylchondrocurarine Di-iodide Dimethyltubocurarine Iodide Trimethyltubocurarine Iodide Metokuriinijodidi Metocurine iodide Metubine iodide Dimetiltubocurarinio, ioduro de Metocurini Iodidum Dimethyl Tubocurarine Iodide
n3:toxicity
Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
n3:proteinBinding
35% in plasma
n3:synthesisReference
Bray, M.D.; U.S. Patent 2,581,903; January 8, 1952; assigned to Eli Lilly and Company.
n17:hasConcept
n18:M0102457
n3:IUPAC-Name
n4:271B47CD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B47D3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B47D2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47CF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47D0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B47D1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B47CB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B47C9-363D-11E5-9242-09173F13E4C5 n4:271B47CC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47CA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B47D9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B47DA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B47D4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B47D5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B47D7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B47D6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B47D8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7601-55-0
n3:Bioavailability
n4:271B47DF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B47E1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B47E2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B47E3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B47DE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B47DD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B47E0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47CE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B47DB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B47DC-363D-11E5-9242-09173F13E4C5